A substantial obstacle to the existing treatment of bacterial diseases is the lack of specific probes that can be used to diagnose and treat pathogenic bacteria in a selective manner while leaving the microbiome largely intact. To tackle this problem, there is an urgent need to develop pathogen-specific therapeutics and diagnostics. Here, we describe recent evidence that indicates distinctive glycans found exclusively on pathogenic bacteria could form the basis of targeted therapeutic and diagnostic strategies. In particular, we highlight the use of metabolic oligosaccharide engineering to covalently deliver therapeutics and imaging agents to bacterial glycans.
The sequences of four mitochondrial genes were determined for Demodex mites isolated from two distantly related species within the family Cervidae, and identified morphologically as belonging to the species Demodex kutzeri. The sequences were used to test the hypothesis that Demodex are strictly host-specific, and hence cospeciate with their hosts: (1) The estimated divergence time between mites found on elk vs humans agreed closely with a previous estimate of the time that these host species last shared a common ancestor, suggesting cospeciation of mites and hosts, at least over long evolutionary timescales. (2) The extremely low levels of sequence divergence between the mites found on elk vs mule deer hosts indicated that these mites belong to the same species, which suggests that Demodex are able to move across host species boundaries over shorter timescales. Together, the results are consistent with the model that Demodex mites are not strict host-specialists, but instead lose the ability to move between host lineages gradually.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.